Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12871696 | 1.00 | HSD17B10 (0.34) | HSD17B10KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1177014 | 1.00 | HSD17B10 (0.34) | HSD17B10KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL12871718 | 0.82 | — | — | |
| SCHEMBL12885766 | 0.79 | — | — | |
| SCHEMBL1176769 | 0.78 | KDM4E (0.36) | HSD17B10KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1176770 | 0.78 | KDM4E (0.36) | HSD17B10KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL14531024 | 0.78 | KDM4E (0.36) | HSD17B10KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL1912779 | 0.68 | BRD4 (0.32) | KDM4EALDH1A1HPGDNPSR1MAPT | |
| SCHEMBL9153017 | 0.67 | — | — | |
| SCHEMBL10606036 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945605-B1 | PROCESS FOR PREPARING SUBSTITUTED ANISIDINES | BOEHRINGER INGELHEIM INT (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-7884246-B2 | starting from substituted cyclic hydroxy-ketones via aromatization through a substituted oxime intermediate; avoids the use of cryogenic conditions, minimizes the number of operations for an overall faster cycle time; in the preperation of drugs for hepatitis C viral infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7884246-B2 | starting from substituted cyclic hydroxy-ketones via aromatization through a substituted oxime intermediate; avoids the use of cryogenic conditions, minimizes the number of operations for an overall faster cycle time; in the preperation of drugs for hepatitis C viral infections | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-20080293972-A1 | Process for Preparing Substituted Anisidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293972-A1 | Process for Preparing Substituted Anisidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1945605-A1 | PROCESS FOR PREPARING SUBSTITUTED ANISIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007053755-A1 | PROCESS FOR PREPARING SUBSTITUTED ANISIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293972-A1 | Process for Preparing Substituted Anisidines | ALKBH3, ALKBH1, ALK | HSD17B10 792/4885KDM4E 676/4885ALDH1A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.